Cannabis - from cultivar to chemovar A. Hazekamp and J. T. Fischedick Drug Testing and Analysis, 2012, (wileyonlinelibrary.com) DOI 10.1002/dta.407, Copyright © 2012 John Wiley & Sons, Ltd. Abstract : The medicinal use of Cannabis is increasing as countries worldwide are setting up official programs to provide patients with access to safe sources of medicinal-grade Cannabis. An important question that remains to be answered is which of the many varieties of Cannabis should be made available for medicinal use. Drug varieties of Cannabis are commonly distinguished through the use of popular names, with a major distinction being made between Indica and Sativa types. Although more than [...]
Lire la suiteLA LÉGALISATION DU CANNABIS AU CANADA, GENÈSE ET ENJEUX DE LA RÉFORME Ivana Obradovic Observatoire Français des Drogues et Toxicomanies, Note n° 2018-04 Saint-Denis, le 11 octobre 2018 Introduction Pourquoi légaliser ? Contexte et objectifs de réforme Contexte et dynamique de la réforme État des lieux des consommations Un historique de réformes Un argument politique et électoral Reprendre la main sur le marché du cannabis médical Assécher le marché noir Des intérêts financiers considérables Légaliser pour mieux encadrer : les paris de la régulation Des objectifs multiples et parfois concurrents Un accès interdit pour les mineurs, contrôlé pour les adultes À la recherche d’une troisième voie entre Uruguay et États-Unis Comment réguler ? De la théorie à [...]
Lire la suiteCannabis use and mental health: risks and benefits Wayne HALL, · Eva HOCH, · Valentina LORENZETTI European Archives of Psychiatry and Clinical Neuroscience, february 2019 https://doi.org/10.1007/s00406-019-00986-2 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 In public debates about cannabis policy, two competing claims are often made about how cannabis use may affect mental health. One is that cannabis use by young adults and vulnerable individuals across the lifespan can be a contributory cause of : a cannabis dependence syndrome; schizophreniform psychoses; anxiety and depressive disorders; acute and perhaps chronic cognitive impairment, and structural and functional changes in brain pathways implicated in reward, learning and [...]
Lire la suiteThe Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury Lital MAJID, Sami HEYMAN, Merav ELGALI ... Esther SHOHAMI et al. Journal of Neurotrauma, Nov 2018, 36, 1-11 DOI: 10.1089/neu.2018.6063 Abstract : Cannabis is one of the most widely used plant drugs in the world today. In spite of the large number of scientific reports on medical marijuana, there still exists much controversy surrounding its use and the potential for abuse due to the undesirable psychotropic effects. However, recent developments in medicinal chemistry of novel non-psychoactive synthetic cannabinoids have indicated that it is possible to separate some of the therapeutic effects [...]
Lire la suiteCultural Neurophenomenology of Psychedelic Thought: Guiding the “Unconstrained” Mind Through Ritual Context Michael LIFSHITZ, Eli SHEINER, and Laurence J. KIRMAYER The Oxford Handbook of Spontaneous Thought : Mind-Wandering, Creativity, and Dreaming Edited by Kalina Christoff and Kieran C.R. Fox, avril 2018 Abstract : This chapter explores psychedelics as catalysts of spontaneous thought. Classic serotonergic psychedelics such as psilocybin, LSD, and ayahuasca can induce potent alterations in cognition and perception. The chapter reviews research on these substances through the lens of cultural neurophenomenology, which aims to trace how neurobiology and sociocultural factors interact to shape experience. After a decades-long hiatus, the scientific study of psychedelics is rediscovering [...]
Lire la suiteIs cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms ? José Alexandre S. CRIPPA,· Jaime E. C. HALLAK, · Antônio W. ZUARDI · Francisco S. GUIMARAES, · Vitor TUMAS, · Rafael G. dos SANTOS European Archives of Psychiatry and Clinical Neuroscience, 2019, 269(1) DOI : 10.1007/s00406-019-00982-6 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. PD is also characterized by non-motor symptoms such as sleep disturbances, cognitive deficits, and psychiatric disorders such as psychosis, depression, and anxiety. The pharmacological treatment for these symptoms is [...]
Lire la suiteEmerging Trends in Cannabis Administration Among Adolescent Cannabis Users Ashley A. KNAPP, Dustin C. LEE, Jacob BORODOVSKY, Alan J. BUDNEY et al. Journal of Adolescent Health, July 2017 ABSTRACT Purpose : The legal landscape of cannabis availability and use in the United States is rapidly changing. As the heterogeneity of cannabis products andmethods of use increases, more information is needed on how these changes affect use, especially in vulnerable populations suchas youth. Methods : A national sample of adolescents aged 14-18 years (N=2,630) were recruited on line through advertisements displayed on Facebook and Instagram to complete a survey on cannabis. The survey assessed patterns of [...]
Lire la suiteCannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report Amanda REIMAN, Mark WELTY, Perry SOLOMON Cannabis and Cannabinoid Research, 2017, Vol 2, n°1 Abstract Introduction: Prescription drug overdoses are the leading cause of accidental death in the United States. Alternatives to opioids for the treatment of pain are necessary to address this issue. Cannabis can be an effective treatment for pain, greatly reduces the chance of dependence, and eliminates the risk of fatal overdose compared to opioid-based medications. Medical cannabis patients report that cannabis is just as effective, if not more, than opioid-based medications for pain. Materials and Methods: The current study examined the [...]
Lire la suiteAn Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies Kerstin IFFLAND, Franjo GROTENHERMEN Cannabis and Cannabinoid Research, 2017, 2, (1), 139–154. DOI: 10.1089/can.2016.0034 https://www.liebertpub.com/doi/10.1089/can.2016.0034?utm_source=sfmc&utm_medium=email&utm_campaign=CAN%20OA%20Feb%201%202019&d=2/1/2019&mcid=1909944349 Abstract Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs. Results: In general, the often described favorable safety profile of CBD in humans was confirmed and extended by the reviewed research. The majority of studies were performed for treatment of epilepsy [...]
Lire la suiteUN CADRE POUR LA LÉGALISATION ET LA RÉGLEMENTATION DU CANNABIS AU CANADA LE RAPPORT FINAL DU GROUPE DE TRAVAIL SUR LA LÉGALISATION ET LA RÉGLEMENTATION DU CANNABIS, Gouvernement du Canada décembre 2016 Table des matières Avant-propos. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Sommaire. . . . . . . [...]
Lire la suite